One way psychiatric disorders differ from neurological disorders is by the absence of anatomically defined neuropathology. “Alzheimer's disease, Parkinson's disease or stroke have a very clear picture of what cells are changing and how they're changing. The specific changes are very clear under a microscope, but in psychiatric diseases one hasn't been able to see that,” Daniel Geschwind told BioWorld. Read More

Myc-associated factor X (MAX), the protein that forms dimers with Myc, could hold the key to blocking one of the most intractable oncogenes. Scientists at the University of Chicago have designed a synthetic molecule that effectively mimics a module of MAX's binding domain. In parallel, the Omomyc protein OMO-103, developed by researchers at the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, successfully completed a phase I clinical trial. From different therapeutic perspectives, both approaches corner Myc and predict the advance of this slow line of research. Read More

Researchers from Zealand Pharma A/S have presented details on their investigation of ZP-6590 as an antiobesity and antiemetic drug in mice. Read More

The Alborada Drug Discovery Institute (ADDI) will collaborate with YD Global Life Science Co. Ltd. (YDGLS) to develop inhibitors of the unfolded protein response for the treatment of diseases that cause dementia. Read More

Promidis Srl has presented results from preclinical evaluations of potent capsid assembly modulators (CAMs) to prevent abnormal accumulation of empty capsids and associated T-cell-mediated liver injury. Read More

Myocardial infarction, a result of uncontrolled heart disease, often results in death. Read More

Nuvalent Inc. has disclosed amino-substituted heterocycles acting as HER2 (erbB2) (mutant) inhibitors reported to be useful for the treatment of cancer. Read More

MGFB, a subsidiary of Fairwinds Bio, has entered into a patent license agreement with Mayo Clinic to advance experimental cancer vaccine therapeutics based on a novel platform developed at Mayo. Read More

Plexium Inc. has synthesized bromodomain-containing protein 4 (BRD4; HUNK1) inhibitors or degraders reported to be useful for the treatment of cancer. Read More

Nabriva Therapeutics AG has identified 12-epi-mutilin derivatives reported to be useful for the treatment of bacterial infection. Read More

G protein-coupled receptor 183 (GPR183/EBI2) is one of the key regulators of the innate immune system, and it has been shown to be upregulated in multiple sclerosis (MS) plaques. In a recently reported study, researchers from Medical University of Gdansk evaluated the effects of pharmacological modulation of GPR183 signaling on remyelination. Read More

Neuropn Therapeutics LLC has divulged piperidine urea derivatives as bifunctional epoxide hydrolase 2 (EPHX2; sEH) inhibitors reported to be useful for the treatment of Parkinson's disease, pain, inflammation and neurodegeneration. Read More

Researchers from Children's Hospital Los Angeles presented data from a study that linked a homozygous missense mutation in ARSK to a new subtype of the lysosomal storage disease mucopolysaccharidoses (MPS). Read More

Researchers from Scorpion Therapeutics Inc. presented preclinical data for the novel EGFR exon 20 mutant inhibitor STX-721, being developed for the treatment of non-small-cell lung cancer (NSCLC). Read More

Orion Corp. has described transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer, musculoskeletal and neuropathic pain. Read More